Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Trogarzonon Dec 28, 2022 8:07pm
113 Views
Post# 35194589

RE:RE:RE:An optimist's view

RE:RE:RE:An optimist's viewNo partner after 2 years of search.  The main problem is the other players have pills and the FDA.  The fda because the endpoints are unattainable at the moment and everybody's failing at it.   Madrigal had success but note that it's not approved yet.  Until fda changes the rules I don't have faith in their program. Th1902 is a money pit in exploratory mode that has'nt demonstrated a clear proof of concept yet after 1.5 year.  So we are priced as legacy drug company with too much expenses and dept at 13%+.  I don't know how they rebuilt anything from here on, because they haven't put anything in front of us yet.  The only thing we see is that ambulance chaser stuff coming up every day of the week.  Anyway the only thing I can do about it will be in May.
<< Previous
Bullboard Posts
Next >>